Articles related to ANTIDEPRESSANTS

The advent of zuranolone may be going beyond postpartum depression, with 87.5% of patients noticing improvements within the first week of treatment for MDD.

Recent findings indicate a significant association between SSRI use in children and delayed puberty, with an odds ratio of 1.44. This underscores the importance of considering potential developmental impacts when prescribing these medications.

With more than 5,000 patients studied in clinical trials, Exxua has demonstrated effectiveness for relieving depressive symptoms with an acceptable side effect profile.

Stay informed about the latest research on factors influencing COVID-19 outcomes. Learn more about how these findings could influence your approach to patient care.

Discover how Exxua, the newly FDA-approved antidepressant, could be a game-changer in treating major depressive disorder, backed by robust clinical trials and a manageable side effect profile.

Explore how a paradigm shift from monoamine to GABAergic systems could offer new, more effective treatments for major depressive disorder; the latest review discusses the unmet needs and the promising potential of NAS GABAA receptor PAMs.